 Treatment of patients with type 2 Diabetes Mellitus DM consists of reducing hyperglycemia through diet, exercise, oral drug therapy or insulin 1. The Thiazolidinedione TZDs, which include Troglitazone withdrawn by the FDA, Rosiglitazone, and Pioglitazone, correct hyperglycemia by increasing insulin sensitivity in both the liver 2, 3 and skeletal muscles 4,5. Although TZDs improve glycemic control in type 2 diabetic subjects, when these agents are administered to non-diabetic subjects they do not affect fasting plasma glucose levels. Nolan et al. 6 observed no effect on the plasma glucose levels of non-diabetic subjects treated with Troglitazone 200 mg twice daily. 